[Ranitidine, a new histamine H2 receptor antagonist. First experimental and clinical data].
The new developed histamine H2-receptor antagonist ranitidine has proven to be a more potent and longer acting anti-secretory compound than cimetidine both after intravenous as well as oral administration. A daily dose of 200-300 mg ranitidine should correspond to 1.0-1.2 g cimetidine in the acute therapy of duodenal ulcer disease. Ranitidine acts neither as a dopamine receptor blocker nor as a dopamine agonist at the pituitary level. Antiandrogenic properties of ranitidine have not yet been described. Ranitidine a more powerful and more selective inhibitor of gastric acid secretion, provides an alternative to cimetidine for clinical situation in which blockage of histamine H2-receptors is useful.
D000818:Animals; D001682:Biological Availability; D002927:Cimetidine / Q000627:therapeutic use; D004285:Dogs; D004381:Duodenal Ulcer / Q000188:drug therapy*; D005663:Furans / Q000378:metabolism / Q000627:therapeutic use*; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000187:drug effects; D006635:Histamine H2 Antagonists / Q000494:pharmacology*; D006801:Humans; D008968:Molecular Conformation; D011899:Ranitidine; D051381:Rats
D005663:Furans; D006635:Histamine H2 Antagonists; D002927:Cimetidine; D011899:Ranitidine
Ranitidina, un nuovo antagonista dei recettori istaminergici H2. Primi dati sperimentali e clinici.